THE APEX TIMES
Los Angeles jury awards $32 million against Johnson & Johnson in asbestos-tainted talc case
The verdict stems from a lawsuit alleging pleural mesothelioma caused by years of exposure to asbestos-contaminated talc linked to the company’s baby powder products.
A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma, according to reporting carried by Yahoo Finance. The case alleges that the woman’s exposure occurred through an asbestos-contaminated talc product sold under the Johnson & Johnson brand, with jurors concluding the company was responsible.
The verdict adds to Johnson & Johnson’s long-running exposure to talc-related litigation, which has focused on whether certain talc used in consumer products was contaminated with asbestos and whether that contamination caused cancers. Pleural mesothelioma is a malignancy associated with asbestos exposure, typically after years of latency.
In related reporting, lawyers have argued to jurors for punitive damages in California talc trials, contending the evidence shows the company knowingly faced risk from its talc supply. One legal report described the Los Angeles matter as part of the growing wave of California bellwether cases, including those seeking to connect Johnson & Johnson’s baby powder to asbestos contamination.
The $32 million award is not the first major talc verdict involving Johnson & Johnson. In March, Reuters reported that a judge threw out a jury’s award directing Johnson & Johnson to pay nearly $1 billion in punitive damages in a prior talc trial, underscoring that outcomes can shift after post-trial motions and appellate review.
Taken together, the verdict and the procedural history illustrate how the talc litigation remains in motion, with juries determining liability and damages while courts later revisit those decisions. For Johnson & Johnson, which has faced thousands of claims, each trial can influence future cases even when individual awards may later be reduced or overturned.
Company and sector context: Johnson & Johnson has repeatedly denied wrongdoing in talc cases and has said it stands by its products and manufacturing. Still, the persistent California trial calendar highlights how state courts have become a key venue for plaintiffs pursuing injury claims tied to talc and asbestos contamination.
What is not disclosed in the Yahoo Finance report is equally important. The article does not spell out the company’s specific trial defenses, whether the verdict included punitive damages on top of compensatory damages, or how the court handled expert testimony, causation evidence, or any evidentiary rulings. Those details typically emerge in later filings and follow-on coverage.
Going forward, investors and industry watchers will likely track whether Johnson & Johnson appeals or seeks post-verdict relief, and whether courts in California continue to treat the case as another bellwether for damages and causation standards. Additional reporting is also likely to clarify how the jury allocated blame and what timeline of exposure the plaintiffs presented.
Why It Matters
- More trial verdicts can affect the pace and posture of ongoing talc litigation, including settlement leverage and future trial strategies.
- Even when large jury awards are later challenged, they can shape judicial and juror perceptions about evidence tied to talc sourcing and causation.
- Procedural outcomes, such as reductions or reversals of punitive damages, can materially change expected costs and risk over time.
- For Johnson & Johnson, repeated adverse jury decisions keep talc litigation in the spotlight for product-liability risk and corporate reputation.
Sources
Key Facts
- A Los Angeles jury awarded $32 million to a family in an asbestos-related talc case involving pleural mesothelioma.
- The reporting says the plaintiff died in 2024 and that the lawsuit alleged exposure to asbestos-contaminated talc in a Johnson & Johnson product.
- The case was decided in Los Angeles, California.
- A separate legal-development report described California talc trials as increasingly focused on punitive damages arguments and on alleged asbestos contamination tied to baby powder.
- Reuters reported that a judge previously threw out a nearly $1 billion punitive damages award against Johnson & Johnson in another talc trial.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
Pfizer highlights Padcev while pushing forward PF-08634404 as part of its longer-term oncology plan
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.